These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9532610)

  • 1. Cardiovascular pharmacology of SKP-450, a new potassium channel activator, and its major metabolites SKP-818 and SKP-310.
    Shin HS; Seo HW; Yoo SE; Lee BH
    Pharmacology; 1998 Mar; 56(3):111-24. PubMed ID: 9532610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic profile of SKP-450, a new potassium-channel activator.
    Lee BH; Yoo SE; Shin HS
    J Cardiovasc Pharmacol; 1998 Jan; 31(1):85-94. PubMed ID: 9456282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive effects of the novel potassium channel activator SKP-450 and its major metabolites in rats.
    Shin HS; Seo HW; Oh JH; Lee BH
    Arzneimittelforschung; 1998 Oct; 48(10):969-78. PubMed ID: 9825113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
    Katz LB; Giardino EC; Salata JJ; Moore JB; Falotico R
    J Pharmacol Exp Ther; 1993 Nov; 267(2):648-56. PubMed ID: 8246137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antihypertensive and cardioprotective effects of (-)-MJ-451, an ATP-sensitive K(+) channel opener.
    Lee YM; Yen MH; Peng YY; Sheu JR; Chen YC; Chang MJ; Cheng CY
    Eur J Pharmacol; 2000 May; 397(1):151-60. PubMed ID: 10844109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profiles of SKP-450 and its family, a K+ channel opener, in comparison with levcromakalim.
    Hong KW; Shin HS; Kim CD; Shin YW; Yoo Se
    Pharmacol Res; 1998 Sep; 38(3):191-7. PubMed ID: 9782069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional hemodynamic dose-response of lemakalim and glybenclamide in anesthetized rats.
    Smits GJ; Perrone MH; Cox BF
    J Cardiovasc Pharmacol; 1997 Jan; 29(1):49-56. PubMed ID: 9007670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular effects of KRN2391 in anesthetized dogs: a comparison with cromakalim and nitroglycerin.
    Kaneta S; Yokoyama T; Izumi H; Izawa T; Ogawa N
    Arch Int Pharmacodyn Ther; 1994; 327(2):184-93. PubMed ID: 7979827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardioprotective effects of KR-30450, a novel K+(ATP) opener, and its major metabolite KR-30818 on isolated rat hearts.
    Jung YS; Moon CH; Cho TS; Yoo SE; Shin HS
    Jpn J Pharmacol; 1998 Jan; 76(1):65-73. PubMed ID: 9517406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic profiles of YM934, a novel potassium channel opener.
    Uchida W; Masuda N; Taguchi T; Shibasaki K; Shirai Y; Asano M; Matsumoto Y; Tsuzuki R; Fujikura T; Takenaka T
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):180-7. PubMed ID: 7511745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of KRN4884, a novel K channel opener, on the cardiovascular system in anesthetized dogs: a comparison with levcromakalim, nilvadipine, and nifedipine.
    Izumi H; Jinno Y; Kaneta S; Tanaka Y; Okada Y; Izawa T; Ogawa N
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):189-97. PubMed ID: 7475042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular profile of RWJ 29009, a new potassium channel activator, in anesthetized and conscious dogs.
    Damiano BP; Giardino EC; Haertlein BJ; Stump GL; Mitchell JA; Falotico R
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):300-10. PubMed ID: 7511761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic and cardiac effects of BMS-180448, a novel K+ATP opener, in anesthetized dogs and isolated rat hearts.
    D'Alonzo AJ; Grover GJ; Darbenzio RB; Sewter JC; Hess TA; Dzwonczyk S; Sleph PG
    Pharmacology; 1996 Feb; 52(2):101-12. PubMed ID: 8851631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Action of KC-399, a newly synthesized potassium channel opener, on mechanical activity and 86Rb efflux in rat aorta.
    Tamura K; Suzuki Y; Yoshida S; Nabata H
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):220-6. PubMed ID: 7511750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. K+ channel opening mediates the vasorelaxant effects of nicorandil in the intact vascular system.
    Cavero I; Pratz J; Mondot S
    Z Kardiol; 1991; 80 Suppl 7():35-41. PubMed ID: 1838848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of vasodilator effects of the potassium channel openers NIP-121 and levcromakalim in dogs and rats.
    Yamashita T; Masuda Y; Kawamura N; Fujikura N; Tanaka S
    Jpn J Pharmacol; 1995 Jun; 68(2):145-52. PubMed ID: 7563971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of a newly synthesized ATP-sensitive potassium channel opener, MJ-355, on blood pressure and myocardial ischemia-reperfusion injury in rats.
    Lee YM; Peng YY; Sheu JR; Cheng CY; Yen MH
    Jpn J Pharmacol; 1999 Oct; 81(2):185-93. PubMed ID: 10591476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effects of the novel potassium channel opener UR-8225.
    Tamargo J; Pérez O; Delpón E; García-Rafanell J; Gómez L; Cavalcanti F
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):295-305. PubMed ID: 7475055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a K+ATP channel opener, lemakalim, on systemic, coronary and regional vascular dynamics in conscious dogs: comparison with nifedipine, adenosine, nitroglycerin and acetylcholine.
    Shen YT; Vatner SF
    J Pharmacol Exp Ther; 1993 May; 265(2):1026-37. PubMed ID: 8496801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Halothane and enflurane attenuate pulmonary vasodilation mediated by adenosine triphosphate-sensitive potassium channels compared to the conscious state.
    Seki S; Sato K; Nakayama M; Murray PA
    Anesthesiology; 1997 Apr; 86(4):923-35. PubMed ID: 9105237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.